TreatmentTrends

December 2013

TreatmentTrends®: Multiple Sclerosis (EU) 2013

Introduction:

BioTrends Research Group is pleased to announce the continuation of TreatmentTrends®: Multiple Sclerosis in the EU report in 2013.
TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products.
TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  *   Compare perceptions and differences in the management and treatment of MS patients across the EU5 regions (France, Germany, Spain, Italy, and the UK)


  *   Understand the relative MS patient load by disease classification (CIS, RRMS, PRMS, SPMS, and PPMS) and how DMAs are used in each group


  *   Understand product attributes that are most important to neurologists when selecting DMAs and compare the different brands on how they are perceived to perform against each attribute


  *   Understand how the use of each DMA brand is expected to change in the next six months and what factors are driving those trends


  *   Evaluate sales strategies and messaging efforts of DMA therapies


  *   Assess awareness of and interest in DMA therapies that are in late stage development

Scope:

Sample Frame & Methodology:

- ~225 neurologists are complete a 45-minute online quantitative survey with several open-ended questions for quali-tative feedback

To qualify, respondents must meet the following criteria:

- Minimum of 20 patients with relaps-ing remitting multiple sclerosis (RR-MS) under management

- Have been in practice a minimum of 2 years and a maximum of 35 years

- More than 75% of professional time spent in clinical practice

The neurologists are recruited from the France (n=50), Germany (n=50), Italy (n=50), Spain (n=48), and UK (n=28)

Deliverables:

- Final report in powerpoint format

- Complete set of frequency tables, summary statistics, and cross tabulations, including analysis between EU regions, can be provided upon request

- Proprietary question slide deck

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions

Product Coverage:

- Approved: Aubagio, Avonex, Betaferon, Copaxone, Extavia, Gilenya, Lemtrada, Rebif, Tecfidera, Tysabri

- In development: Copaxone 40 mg 3TW, daclizumab, laquinimod, ocrelizumab, Plegridy

Related 2013 Reports:

- TreatmentTrends®: Multiple Sclerosis (US)

- LaunchTrends®: Aubagio

- LaunchTrends®: Lemtrada

- LaunchTrends®: Tecfidera

- DecisionBase®: Multiple Sclerosis - Chronic Progressive

- DecisionBase®: Multiple Sclerosis - Relapsing Remitting

- PatientBase®: Multiple Sclerosis in Mexico

- PatientBase®: Multiple Sclerosis in Turkey

Search Published Reports


Decision Resources Group brands include: